Somewhat Critical Press Coverage Somewhat Unlikely to Impact Invivo Therapeutics (NVIV) Stock Price

News stories about Invivo Therapeutics (NASDAQ:NVIV) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Invivo Therapeutics earned a daily sentiment score of -0.05 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.618614945388 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Invivo Therapeutics (NVIV) remained flat at $$0.69 during trading hours on Friday. 128,090 shares of the company’s stock traded hands, compared to its average volume of 359,815. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.06 and a current ratio of 5.06. Invivo Therapeutics has a 12 month low of $0.60 and a 12 month high of $4.95. The company has a market capitalization of $23.54, a P/E ratio of -0.81 and a beta of 3.21.

Invivo Therapeutics (NASDAQ:NVIV) last released its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). equities analysts forecast that Invivo Therapeutics will post -0.81 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.

Insider Buying and Selling by Quarter for Invivo Therapeutics (NASDAQ:NVIV)

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply